187 related articles for article (PubMed ID: 24063635)
1. Efficacy and tolerability of lanthanum carbonate in treatment of hyperphosphatemia patients receiving dialysis--a systematic review and meta-analysis of randomized controlled trials.
Huang W; Liu J; Tang Y; Gao X; Di B; Zhang F
Curr Med Res Opin; 2014 Jan; 30(1):99-108. PubMed ID: 24063635
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
Joy MS; Finn WF;
Am J Kidney Dis; 2003 Jul; 42(1):96-107. PubMed ID: 12830461
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial.
Takahara Y; Matsuda Y; Takahashi S; Shigematsu T;
Clin Nephrol; 2014 Sep; 82(3):181-90. PubMed ID: 25079863
[TBL] [Abstract][Full Text] [Related]
4. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
Shigematsu T;
Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
[TBL] [Abstract][Full Text] [Related]
5. Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis--system review of lanthanum carbonate.
Guo H; Zhang X; Tang S; Zhang S
Ren Fail; 2013; 35(10):1455-64. PubMed ID: 23992043
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
[TBL] [Abstract][Full Text] [Related]
7. Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis.
Zhao L; Liu A; Xu G
Ren Fail; 2021 Dec; 43(1):1378-1393. PubMed ID: 34602015
[TBL] [Abstract][Full Text] [Related]
8. Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.
Lee YK; Choi HY; Shin SK; Lee HY
Clin Nephrol; 2013 Feb; 79(2):136-42. PubMed ID: 23211335
[TBL] [Abstract][Full Text] [Related]
9. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.
Chiang SS; Chen JB; Yang WC
Clin Nephrol; 2005 Jun; 63(6):461-70. PubMed ID: 15960148
[TBL] [Abstract][Full Text] [Related]
10. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis.
Shigematsu T;
Ther Apher Dial; 2008 Feb; 12(1):55-61. PubMed ID: 18257813
[TBL] [Abstract][Full Text] [Related]
11. Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients.
Hutchison AJ; Gill M; Copley JB; Poole L; Wilson RJ
BMC Nephrol; 2013 Feb; 14():40. PubMed ID: 23418668
[TBL] [Abstract][Full Text] [Related]
12. Effect of Lanthanum Carbonate on All-Cause Mortality in Patients Receiving Maintenance Hemodialysis: a Meta-Analysis of Randomized Controlled Trials.
Wang F; Lu X; Zhang J; Xiong R; Li H; Wang S
Kidney Blood Press Res; 2018; 43(2):536-544. PubMed ID: 29627829
[TBL] [Abstract][Full Text] [Related]
13. Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.
Ogata H; Fukagawa M; Hirakata H; Kagimura T; Fukushima M; Akizawa T;
JAMA; 2021 May; 325(19):1946-1954. PubMed ID: 34003226
[TBL] [Abstract][Full Text] [Related]
14. Meta-Analysis Treatment Hyperphosphatemia Chronic Renal Failure Based on Nano Lanthanum Hydroxide.
Jiang M; Zheng H; Xu C; Wang Y; Wan T
J Nanosci Nanotechnol; 2020 Oct; 20(10):6555-6560. PubMed ID: 32385013
[TBL] [Abstract][Full Text] [Related]
15. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
Shigematsu T;
Clin Nephrol; 2008 Nov; 70(5):404-10. PubMed ID: 19000540
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis.
Vegter S; Tolley K; Keith MS; Postma MJ
Value Health; 2011; 14(6):852-8. PubMed ID: 21914505
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of lanthanum carbonate in German patients on dialysis.
Dellanna F; Reichel H; Seibt F
Clin Nephrol; 2012 Nov; 78(5):382-90. PubMed ID: 22948119
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis.
Finn WF; Joy MS; Hladik G;
Clin Nephrol; 2004 Sep; 62(3):193-201. PubMed ID: 15481851
[TBL] [Abstract][Full Text] [Related]
19. Multicenter study on the long-term (3-year) efficacy of lanthanum carbonate in dialysis patients.
Ando R; Yama S; Ohnishi T; Iwamoto S; Kimura H; Chida Y; Ishida Y; Yamada K; Inagaki Y; Takayama M; Tachibana K; Kikuchi K; Inoue A; Ohtsuka M
Ther Apher Dial; 2014 Jun; 18 Suppl 1():2-8. PubMed ID: 24953759
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients.
Shigematsu T; Ohya M; Negi S; Masumoto AR; Nakashima YM; Iwatani Y; Moribata MK; Yamanaka S; Tatsuta K; Mima T
Contrib Nephrol; 2015; 185():42-55. PubMed ID: 26023014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
